Asenapine: Difference between revisions
m typo |
Updated with latest status from news (sourced) |
||
| Line 26: | Line 26: | ||
}} |
}} |
||
'''Asenapine''' is a new [[5-HT2A receptor|5-HT<sub>2A</sub>-]] and [[dopamine receptor|D2-receptor]] [[antagonist]] |
'''Asenapine''' is a new [[5-HT2A receptor|5-HT<sub>2A</sub>-]] and [[dopamine receptor|D2-receptor]] [[antagonist]] for the treatment of [[schizophrenia]] and acute mania associated with [[bipolar disorder]]. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, minimal weight gain. [[clinical trial]]s. |
||
| title = Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA |
|||
| publisher = Schering-Plough |
|||
| date = [[2007-11-26]] |
|||
| url = http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1080771 |
|||
| accessdate = 2007-11-26 }})</ref> |
|||
Asenapine belongs to a class of neuroleptics known as "[[atypical antipsychotics]]", which have, over the last two decades, become increasingly popular alternatives to "[[typical antipsychotics]]", such as [[haloperidol]]. The manufacturers of asanapine refer to it as a "new generation" or "second generation" atypical antipsychotic. |
Asenapine belongs to a class of neuroleptics known as "[[atypical antipsychotics]]", which have, over the last two decades, become increasingly popular alternatives to "[[typical antipsychotics]]", such as [[haloperidol]]. The manufacturers of asanapine refer to it as a "new generation" or "second generation" atypical antipsychotic. |
||
| Line 32: | Line 37: | ||
Other atypical antipsychotics include [[aripiprazole]], [[olanzapine]], [[quetiapine]], [[risperidone]], and [[ziprasidone]]. |
Other atypical antipsychotics include [[aripiprazole]], [[olanzapine]], [[quetiapine]], [[risperidone]], and [[ziprasidone]]. |
||
==Notes== |
|||
<references /> |
|||
==External links== |
==External links== |
||
Revision as of 01:23, 27 November 2007
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ECHA InfoCard | 100.059.828 |
| Chemical and physical data | |
| Formula | C17H16ClNO |
| Molar mass | 285.77 g/mol g·mol−1 |
Asenapine is a new 5-HT2A- and D2-receptor antagonist under development for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 combination with Organon International. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA accepted the manufacturer's NDA on November 26, 2007 for standard review. [2]
Asenapine belongs to a class of neuroleptics known as "atypical antipsychotics", which have, over the last two decades, become increasingly popular alternatives to "typical antipsychotics", such as haloperidol. The manufacturers of asanapine refer to it as a "new generation" or "second generation" atypical antipsychotic.
Other atypical antipsychotics include aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone.
Notes
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA" (Press release). Schering-Plough. 2007-11-26. Retrieved 2007-11-26.
{{cite press release}}: Check date values in:|date=(help))
External links
Commercial
Third-party
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |